
IndraLab
Statements
reach
"Interference of the protein-protein interaction between the target collapsin response mediator protein 2 (CRMP2) and CaV2.2 in sensory neurons by unique peptides effectively diminishes trafficking of the ion channel to the plasma membrane and serves to attenuate peripheral sensitization in rodent models of inflammation or neuropathic pain (Brittain et al. 2011b, Piekarz et al. 2012, Ripsch et al. 2012, Wilson et al. 2011, Wilson et al. 2012a)."
sparser
"We previously showed that CRMP2 is a novel binding partner of CaV2.2. xref , xref A 15-amino acid peptide derived from CRMP2 (designated CBD3 for calcium channel binding domain) uncoupled the CaV2.2–CRMP2 interaction leading to a decrement in Ca 2+ current and neurotransmitter release and, consequently, suppressed persistent inflammatory and neuropathic hypersensitivity. xref , xref , xref Mutating single residues within the CBD3 peptide sequence or changing the cell-penetrating motif improved the efficacy of CBD3 in models of neuropathic pain. xref , xref Here, we tested the hypothesis that tethering the CBD3 peptide to the membrane with myristate would confine the myristoylated peptide’s action(s) to uncoupling membrane CaV2.2–CRMP2 interactions, block Ca 2+ influx in sensory neurons, and be effective in reducing pain-related behaviors in models of pain."
sparser
"Interference of the protein-protein interaction between the target collapsin response mediator protein 2 (CRMP2) and CaV2.2 in sensory neurons by unique peptides effectively diminishes trafficking of the ion channel to the plasma membrane and serves to attenuate peripheral sensitization in rodent models of inflammation or neuropathic pain ( xref , xref , xref , xref , xref )."
sparser
"The study of CaV2.2 trafficking modulators xref led us to identify axon/dendrite specification collapsin response mediator protein 2 (CRMP2) as a CaV2.2-binding partner, xref which enhances CaV2.2 membrane trafficking and facilitates synaptic transmission. xref , xref CaV2.2 membrane trafficking was effectively disrupted by a 15-amino-acid region of CRMP2, named Ca 2+ channel-binding domain 3 (CBD3). xref Systemic injection of CBD3 peptide conjugated to the cell-penetrating motif of the HIV transduction domain protein tat (tat-CBD3) reduced hypersensitive behavior in chemically induced inflammatory and neuropathic pain models. xref , xref , xref , xref tat-CBD3 reduced CaV2.2-mediated currents by inhibiting CaV2.2–CRMP2 interaction, xref which resulted in reduced nociceptor excitability, diminished neuropeptide release from primary sensory neurons, and lowered excitatory synaptic transmission. xref "
sparser
"Although the precise nature of NF1-linked pain syndromes remains unknown, patients clearly experience pain independent of their tumor burden, and these findings affirm the necessity of CRMP2 in NF1-related pain, while suggesting a physiological role for neurofibromin’s C-terminal domain-mediated inhibition of the CRMP2-Cav2.2 interaction [ xref ]."
sparser
"We previously reported that CBD3, a 15 amino acid fragment of CRMP2, disrupts the CRMP2–CaV2.2 interaction [ xref ] irrespective of the cell penetrating motif it is appended to: the HIV-1 transactivator of transcription domain (TAT) [ xref ], a myristate (Myr) tag [ xref ], or homopolyarginine (R9) [ xref ]."
sparser
"As previously described, CaV2.2–CRMP2 disruption by tat-CBD3 decreased surface CaV2.2 in DRG. xref , xref Myr-tat-CBD3 peptide interfered with the CaV2.2–CRMP2 interaction more efficiently than tat-CBD3 as observed by a reduction in colocalization within minutes of incubation ( xref )."
sparser
"Second , despite being an indirect ‘blocker’ of Ca 2+ influx, ( S )-LCM provides improved efficacy compared to TROX-1, a small-molecule, state-dependent blocker of CaV2 channels [ xref ] as well as a membrane-tethered CRMP2 peptide that uncouples the CRMP2-CaV2.2 interaction that we recently reported [ xref ]."
reach
"Towards this end, we recently identified a short peptide, designated CBD3, derived from collapsin response mediator protein 2 (CRMP-2) that suppressed inflammatory and neuropathic hypersensitivity by inhibiting CRMP-2 binding to CaV2.2 [Brittain et al., Nature Medicine 17:822-829 (2011)]."
sparser
"Interestingly, in this animal model of pain, the peptide is administered systemically after the development of chronic hypersensitivity and is still able to effectively attenuate nociceptive behaviors, suggesting a continued role for the interaction of CRMP-2 and CaV2.2 on neurotransmitter release."
sparser
"Concomitant expression of CaV2.2, CRMP2, and CGRP was detected in a subset of neurons from the ophthalmic branch of TGs that receive input from the dura mater. xref These results suggest a coordinated mechanism involving interactions between CRMP2 and CaV2.2 to facilitate the release of pro-nociceptive CGRP that consequently leads to cephalic pain."
sparser
"Although the control peptides did not alter this interaction, the tat-CBD3 peptide was able to inhibit CaV2.2–CRMP2 interaction by ~43% at 10 μM. Myr-tat-CBD3, in a concentration-dependent manner, attenuated this interaction with greater than ~81% inhibition at 10 μM ( xref ; top blot and xref )."
sparser
"The pharmacological action of peptides observed in our in vitro experiments is linked to uncoupling of the CaV2.2–CRMP2 interaction culminating in alleviation of inflammatory and neuropathic pain. xref , xref , xref , xref , xref Sustained, but incomplete, relief of neuropathic pain has been successfully demonstrated for a nonmyristoylated CRMP2 peptide. xref We postulate that the myristoylated version described herein may afford greater efficacy and clinical utility as a gene therapy strategy for chronic pain."
reach
"The CBD3 peptide bound to immobilized loop 1 and the distal part of the carboxyl terminus of CaV2.2 and in a concentration-dependent fashion, blocked the interaction between recombinantly purified CRMP2 and loop regions of CaV2.2, between full-length native CaV2.2 and recombinantly purified CRMP2, demonstrating usefulness as a tool for interrupting the interaction between this protein complex."
sparser
"Data here demonstrate a novel efficacious compound to inhibit pain without demonstrating any addiction or motor deficits ( xref , xref ) providing an instructive example of how designing peptides tailored to limit membrane CaV2.2–CRMP2 interactions can have a great utility in the treatment of post-surgical and inflammatory pain."
sparser
"Reasoning that the reported superior cell penetrating ability of the nona-arginine CPP ( xref ) may allow for greater uptake of the peptide which may result in superior biochemical and functional uncoupling of the CaV2.2–CRMP2 interaction and suppression of transmitter release from nociceptive neurons culminating in efficacy in chronic pain models, we tested the R9 grafted CBD3 (i.e. ST2-104) peptide in the TNI model of traumatic neuropathy."
sparser
"The authors’ results demonstrated that a direct interaction between CRMP2 and CaV2.2 increases cell surface trafficking of CaV2.2 as well as calcium current density, which leads not only to an increased release of the neurotransmitter glutamate and synaptic vesicle recycling but also impacts axonal growth of hippocampal neurons."
sparser
"These findings are entirely consistent with our previous results demonstrating longer periods of pain-related behavior reversal in the TNI versus the ddC model following systemic injection of a TAT-conjugated peptide from calcium channels that breaks the CaV2.2–CRMP2 interaction ( xref ) as well as with the CRMP2-derived ST1-104 peptide ( xref )."
sparser
"TAT-CBD3 peptide interfered with CRMP2-CaV2.2 interactions resulting in acute inhibition of CaV2.2 currents in sensory and hippocampal neurons; acute inhibition of frequency of spontaneous excitatory postsynaptic currents (sEPSCs) in spinal cord slices as well as layer V pyramidal neurons suggesting reduction in probability of glutamate release from stimulated presynaptic terminals; and inhibition of evoked calcitonin gene-related peptide (CGRP) in sensory neurons in culture (acute and long-term inhibition observed) and in spinal cord slices."
sparser
"To develop a reagent to disrupt the interaction of CRMP-2 with the CaV2.2 complex in vivo , we synthesized a series of overlapping 15-amino-acid peptides covering the entire length of CRMP-2, including three CaV binding domains (CBDs1–3) we had previously identified in vitro as crucial for the CRMP-2–CaV2.2 interaction xref ."
reach
"Interestingly, in this animal model of pain, the peptide is administered systemically after the development of chronic hypersensitivity and is still able to effectively attenuate nociceptive behaviors, suggesting a continued role for the interaction of CRMP-2 and CaV2.2 on neurotransmitter release."
sparser
"We tested the hypothesis that replacement of the TAT motif with the presumably superior cell penetrating prowess of the homopolyarginine motif ( xref ) would prevent CRMP2–CaV2.2 interaction, block Ca 2+ influx in sensory neurons, and be effective in reducing pain-related behavior in various models of peripheral neuropathy."
reach
"Our previous work identified the axonal growth and specification collapsin response mediator protein 2 (CRMP2) as a novel regulator of Cav2.2 activity: direct binding between Cav2.2 and CRMP2 leads to a CRMP2-mediated increase in Ca current density and increased transmitter release in sensory neurons."
sparser
"Towards this end, we recently identified a short peptide, designated CBD3, derived from collapsin response mediator protein 2 (CRMP-2) that suppressed inflammatory and neuropathic hypersensitivity by inhibiting CRMP-2 binding to CaV2.2 [Brittain et al ., Nature Medicine 17:822–829 (2011)]."
reach
"In this model, phosphorylated CRMP2 may play a role in localizing CaV2.2 to presynaptic terminals where the channel can participate in nociceptive transmission.In a series of studies, we identified the axonal CRMP2 as a novel regulator of CaV2.2 activity; direct binding between CaV2.2 and CRMP2 leads to CRMP2-mediated increase in Ca current density and increased transmitter release in sensory neurons."